Thu, Aug 21, 2014, 8:34 AM EDT - U.S. Markets open in 56 mins.

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • akos103 akos103 Jan 18, 2012 2:34 PM Flag

    Another buy rating, $20 target

    Canaccord Genuity Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR) on Continued Positive Script Trends and Aggressive Strategy



    E-mail Address
    More News related to OPTR
    Canaccord Genuity Reiterates a 'Buy' on Optimer Pharmaceuticals (OPTR) on Continued Positive Script Trends and Aggressive Strategy


    January 18, 2012 9:31 AM EST

    Canaccord Genuity reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target of $20.00.

    Canaccord analyst, George Farmer, said, "OPTR reported 2011 DIFICID gross sales of $24.4M, a total of $12.1M in Q3/11 (includes $5.1M to fully-stock inventory) and $12.2M in Q4/11, with strong Q4 m/m growth of ~11%. End of Q4/11 inventory decreased $1.1M, resulting in Q4/11 ex-wholesaler sales of $13.3M, a 90% increase compared to Q3/11 ex-wholesaler sales of $7M. This is reflected in an 87% increase between Q3 and Q4 of wholesale shipments from 2505 to 4675 treatments. DIFICID shipments to wholesalers in Q4/11 grew at an 11.3% compounded monthly growth rate. We now model for the Euro 50M Astellas milestone payment in Q2/12."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OPTR
12.780.00(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.